Erratum: Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort
Erratum: Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Welzel TM, Petersen J, Herzer K, et al. Daclatasvir …
Tania M WelzelJörg PetersenKerstin HerzerPeter FerenciMichael GschwantlerHeiner WedemeyerThomas BergUlrich SpenglerOla WeilandMarc van der ValkJürgen RockstrohMarkus Peck-RadosavljevicYue ZhaoMaria Jesus Jimenez-ExpositoStefan Zeuzem
Gut 2016; 65 1861-1870 Published Online First: 07 Sep 2016. doi: 10.1136/gutjnl-2016-312444
PDF
